オプションチェーンは、Septernaの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Septernaの市場センチメントを評価します。.

Septerna (NASDAQ:SEPN) 株価情報, オプションチェーン

SEPTERNA INC

Septerna

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Septerna Inc

News

Guidance

SQNS

Sequans Communications Sees Q2 Sales $8.000M-$9.000M vs $8.90M Est

General

LIND

Lindblad Expeditions Inks Multi-Year Charter 0Agreement With Transcend Cruises For European River Expeditions

2025 Guidance
Construction and commissioning
<ul>
<li>Expected commissioning of 0.9 FGW of capacity, which is expected to add approximately $148-152m to annualized revenues and income and $129-133m annualized EBITDA, starting in 2026.</li>
<li>Starting construction on 2.9 FGW of capacity, which is expected to add approximately $487-495m in annualized revenues and income and approximately $428-436m in annualized EBITDA gradually through 2026-2027.</li>
</ul>
Financial guidance
<ul>
<li>Total revenues and income for 2025 are expected to range between $490m and $510m. Of the projected revenues and income, 38% are expected to be denominated in ILS, 35% in EUR, and 27% in USD.</li>
<li>Adjusted EBITDA for 2025 is expected to range between $360m and $380m.</li>
<li>Approximately 90% of the electricity volumes expected to be generated in 2025 will be sold at fixed prices through PPAs or hedges.</li>
</ul>

ENLT

Enlight Renewable Energy Affirms FY2025 Sales Guidance of $490.00M-$510.00M

Earnings

Enlight Renewable Energy Q1 2025 EPS $0.75 Beats $0.10 Estimate, Sales $129.87M Beat $99.83M Estimate

Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is maintaining its position amid market uncertainty as traders anticipate the Federal Reserve&#8217;s upcoming policy meeting, with a prominent analyst suggesting the cryptocurrency may have reached its correction low.
What Happened: Cryptocurrency analyst Michaël van de Poppe, founder of MN Consultancy, stated on X that Bitcoin is &#8220;holding up nicely&#8221; despite recent market turbulence. &#8220;I think we&#8217;ll see the low of the correction today-tomorrow. FOMC meeting coming up, standard correction prior to it. Up-only season around the corner,&#8221; van de Poppe wrote.
The leading cryptocurrency traded between $93,000 and $95,000 on Monday, <a href="https://www.benzinga.com/25/05/45212767/bitcoin-ethereum-flat-dogecoin-dips-even-as-trump-calls-crypto-popular-analyst-says-btc-build-up-good-predicts-eth-uptrend-after-fed-meet">hitting an intraday high</a> of $95,193.19. 
Van de Poppe&#8217;s optimism aligns with his earlier predictions. In a separate analysis, he noted that a rally in gold indicates a &#8220;risk-off mentality&#8221; ahead of Wednesday&#8217;s Federal Reserve meeting, but maintained that &#8220;Bitcoin build-up is good.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> still holding up nicely, and I think we&#39;ll see the low of the correction today-tomorrow. FOMC meeting coming up, standard correction prior to it. Up-only season around the corner. <a href="https://t.co/JVjEXNBuQh">pic.twitter.com/JVjEXNBuQh</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1919658915312107720?ref_src=twsrc%5Etfw">May 6, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See More: <a href="https://www.benzinga.com/general/market-summary/25/05/45215376/us-stocks-likely-to-open-lower-after-snapping-9-day-streak-downside-could-be-limited-even-in-a-mild-recession-says-expert">US Stocks Likely To Open Lower After Snapping 9-Day Streak: &#8216;Downside Could Be Limited Even In A Mild Recession,&#8217; Says Expert</a>
Why It Matters: The timing of van de Poppe&#8217;s prediction is significant as markets await the Federal Reserve&#8217;s decision. The CME Group&#8217;s FedWatch tool projects a 98.2% likelihood of the Federal Reserve keeping current <a href="https://www.benzinga.com/25/05/45192387/market-bets-on-aggressive-fed-cuts-clash-with-short-rate-market-data-next-fed-chair-could-initiate-cutting-cycle-says-expert">interest rates unchanged</a> in its May meeting, with a 79.1% chance of a cut after the July meeting.
Competing market analysis from cryptocurrency analyst Benjamin Cowen presents a <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45192498/bitcoins-key-level-is-96500-analyst-warns-but-heres-what-could-trigger-a-breakdown">more cautious view</a>, warning that Bitcoin&#8217;s current pattern resembles its 2019 setup, where BTC surged 42% post-death cross, only to crash to a lower low weeks later. Cowen emphasizes that unless Bitcoin closes above $96,500, the current move could prove to be another fakeout.
The global cryptocurrency market capitalization currently stands at $2.94 trillion, with the market sentiment shifting to &#8220;Greed&#8221; <a href="https://www.benzinga.com/25/05/45212767/bitcoin-ethereum-flat-dogecoin-dips-even-as-trump-calls-crypto-popular-analyst-says-btc-build-up-good-predicts-eth-uptrend-after-fed-meet">according to the Crypto Fear and Greed Index</a>. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45215345/us-commerce-secretary-lutnick-skeptical-of-trade-deal-with-canadas-socialist-regime-ahead-of-trump-carney-meeting-theyve-been-basically-feeding-off-of-us-for-decades-upon-decades">US Commerce Secretary Lutnick Skeptical Of Trade Deal With Canada&#8217;s &#8216;Socialist Regime&#8217; Ahead Of Trump-Carney Meeting: &#8216;They&#8217;ve Been Basically Feeding Off Of Us For Decades Upon Decades..&#8217;</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Economics

Federal Reserve

$BTC

Bitcoin's 'Up-Only Season Around The Corner,' Says Analyst Michaël van de Poppe, Predicts BTC Will Bottom Ahead Of FOMC Meeting

2025 GUIDANCE AND LONG-TERM TARGETS
NW Natural Holdings updated 2025 GAAP EPS guidance to $2.65 to $2.85 (from the previous range of $2.66 to $2.86) as a result of the expected transaction costs from the Hughes acquisition. NW Natural Holdings reaffirmed adjusted EPS guidance of $2.75 to $2.95 on a non-GAAP1 basis excluding the $5.8 million pre-tax transaction costs associated with the acquisitions of SiEnergy and Hughes (approximately $4.3 million or $0.10 per share after-tax2). This guidance assumes continued customer growth, average weather conditions, and no significant changes in prevailing regulatory policies, mechanisms, or assumed outcomes, or significant local, state or federal laws, legislation or regulations.
NW Natural Holdings reaffirmed its long-term EPS growth rate target of 4% to 6% compounded annually from the expected 2025 adjusted EPS3.
We expect NW Natural Holdings capital expenditures for 2025 to be in the range of $450 - $500 million. The timing and amount of the capital expenditures and projects for 2025 or additional investments in our infrastructure during or after 2025 could change based on customer growth, significant changes in prevailing regulatory policies or outcomes, or significant local, state or federal laws, legislation or regulations, or cost estimates. Required funds for the investments are expected to be internally generated or financed with long-term debt or equity, as appropriate.

Northwest Natural Lowers FY25 GAAP EPS Guidance From $2.66-$2.86 To $2.65-$2.85 vs $2.85 Est; Reaffirmed Adj. EPS guidance of $2.75-$2.953 Vs. $2.87 Est.

WIIM

Ford shares are trading lower after the company suspended its financial guidance due to tariff-related uncertainty.

Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) affirms FY2025 Adj EPS guidance from $5.75-$6.85 to $5.75-$6.85 vs $6.17 analyst estimate..

ATKR

Atkore Affirms FY2025 Adj EPS Guidance of $5.75-$6.85 vs $6.17 Est, Maintains Adjusted EBITDA Outlook Of $375M-$425M

Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) sees Q2 sales of $157.000 million-$159.000 million vs $158.34 million analyst estimate.

LMND

Lemonade Sees Q2 Sales $157.000M-$159.000M vs $158.34M Est

PLTR

Palantir Technologies shares are trading lower after the company reported Q1 financial results.

CANG

Cango Produced 470 Bitcoins In April Vs. 530 In March

Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) raises FY2025 sales outlook from $655.00 million-$657.00 million to $661.00 million-$663.00 million vs $658.61 million estimate.

Lemonade Raises FY2025 Sales Guidance from $655.00M-$657.00M to $661.00M-$663.00M vs $658.61M Est

Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.92) by 6.52 percent. This is a 28.36 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $151.20 million which beat the analyst consensus estimate of $145.21 million by 4.13 percent. This is a 26.95 percent increase over sales of $119.10 million the same period last year.

Earnings Beats

Lemonade Q1 EPS $(0.86) Beats $(0.92) Estimate, Sales $151.20M Beat $145.21M Estimate

<ul>
<li>Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability.</li>
<li>Targeting to present clinical data of over 40 SCLC patients, including the dose escalation and expansion, from partner Hengrui at medical conference in Q3 2025</li>
</ul>

Biotech

Health Care

IDYA

The FDA Clears Ideaya Biosciences' Investigational New Drug Application To Initiate A Phase 1 Trial To Evaluate IDE849 (SHR-4849), A Potential First-in-class Delta-like Ligand 3-targeting Topo-i-payload Antibody Drug Conjugate Program, In Solid Tumors

Northwest Natural Hldg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $1.96 by 16.33 percent. This is a 34.91 percent increase over earnings of $1.69 per share from the same period last year. The company reported quarterly sales of $494.28 million which beat the analyst consensus estimate of $475.98 million by 3.85 percent. This is a 14.03 percent increase over sales of $433.47 million the same period last year.

Northwest Natural Hldg Q1 Adj. EPS $2.28 Beats $1.96 Estimate, Sales $494.28M Beat $475.98M Estimate

Centerra Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGAU#NYSE">CGAU</a>) reported quarterly earnings of $0.12 per share which beat the analyst consensus estimate of $0.10 by 20 percent. This is a 14.29 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $299.50 million which beat the analyst consensus estimate of $290.04 million by 3.26 percent. This is a 2.06 percent decrease over sales of $305.80 million the same period last year.

CGAU

Centerra Gold Q1 Adj. EPS $0.12 Beats $0.10 Estimate, Sales $299.50M Beat $290.04M Estimate

Centerra Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CG#TSX">CG</a>) reported quarterly earnings of $0.13 per share which met the analyst consensus estimate. This is a 13.33 percent decrease over earnings of $0.15 per share from the same period last year. The company reported quarterly sales of $299.50 million which beat the analyst consensus estimate of $283.02 million by 5.82 percent. This is a 2.06 percent decrease over sales of $305.80 million the same period last year.

TSX:CG

Centerra Gold Q1 Adj. EPS $0.13, Inline, Sales $299.50M Beat $283.02M Estimate

Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) reported quarterly earnings of $2.08 per share which beat the analyst consensus estimate of $1.49 by 39.6 percent. This is a 49.02 percent decrease over earnings of $4.08 per share from the same period last year. The company reported quarterly sales of $701.73 million which beat the analyst consensus estimate of $690.83 million by 1.58 percent. This is a 11.50 percent decrease over sales of $792.91 million the same period last year.

Atkore Q2 Adj. EPS $2.08 Beats $1.49 Estimate, Sales $701.73M Beat $690.83M Estimate

KBR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBR#NYSE">KBR</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.86 by 13.95 percent. This is a 27.27 percent increase over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $2.06 billion which missed the analyst consensus estimate of $2.07 billion by 0.80 percent. This is a 13.04 percent increase over sales of $1.82 billion the same period last year.

Earnings Misses

KBR Q1 Adj. EPS $0.98 Beats $0.86 Estimate, Sales $2.06B Miss $2.07B Estimate

Ball (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) reported quarterly earnings of $0.76 per share which beat the analyst consensus estimate of $0.70 by 8.57 percent. This is a 11.76 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $3.10 billion which beat the analyst consensus estimate of $2.89 billion by 7.02 percent. This is a 7.76 percent increase over sales of $2.87 billion the same period last year.

BALL

Ball Q1 Adj. EPS $0.76 Beats $0.70 Estimate, Sales $3.10B Beat $2.89B Estimate

Press Releases

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Legal

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Kirby McInerney LLP Announces Investigation Against Septerna, Inc. (SEPN) on Behalf of Investors

SEPTERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Septerna, Inc. on Behalf of Septerna Stockholders and Encourages Investors to Contact the Firm

Comments

Septerna

Septerna (SEPN) オプション

Septerna (NASDAQ:SEPN) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル